Innovent Biologics IVBXF Stock
Innovent Biologics Price Chart
Innovent Biologics IVBXF Financial and Trading Overview
| Innovent Biologics stock price | 12 USD |
| Previous Close | 12.51 USD |
| Open | 12.51 USD |
| Bid | 12.01 USD x 30000 |
| Ask | 13 USD x 30000 |
| Day's Range | 12.51 - 12.51 USD |
| 52 Week Range | 9.1 - 15.01 USD |
| Volume | 5K USD |
| Avg. Volume | 1.77K USD |
| Market Cap | 21.28B USD |
| Beta (5Y Monthly) | 0.328 |
| PE Ratio (TTM) | 122 |
| EPS (TTM) | 0.1 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
IVBXF Valuation Measures
| Enterprise Value | 3.53B USD |
| Trailing P/E | 122 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | 0.9 |
| Price/Sales (ttm) | 1.3545675 |
| Price/Book (mrq) | 6.8534813 |
| Enterprise Value/Revenue | 0.225 |
| Enterprise Value/EBITDA | 1.956 |
Trading Information
Innovent Biologics Stock Price History
| Beta (5Y Monthly) | 0.328 |
| 52-Week Change | -1.77% |
| S&P500 52-Week Change | 15.77% |
| 52 Week High | 15.01 USD |
| 52 Week Low | 9.1 USD |
| 50-Day Moving Average | 12.56 USD |
| 200-Day Moving Average | 11.17 USD |
IVBXF Share Statistics
| Avg. Volume (3 month) | 1.77K USD |
| Avg. Daily Volume (10-Days) | 1.57K USD |
| Shares Outstanding | 1.74B |
| Float | 1.61B |
| Short Ratio | N/A |
| % Held by Insiders | 6.23% |
| % Held by Institutions | 55.44% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 7.84% |
| Operating Margin (ttm) | 13.98% |
| Gross Margin | 76.51% |
| EBITDA Margin | 11.48% |
Management Effectiveness
| Return on Assets (ttm) | 2.23% |
| Return on Equity (ttm) | 7.00% |
Income Statement
| Revenue (ttm) | 15.71B USD |
| Revenue Per Share (ttm) | 9.14 USD |
| Quarterly Revenue Growth (yoy) | 44.80% |
| Gross Profit (ttm) | 12.02B USD |
| EBITDA | 1.8B USD |
| Net Income Avi to Common (ttm) | 1.23B USD |
| Diluted EPS (ttm) | 0.1 |
| Quarterly Earnings Growth (yoy) | 50.20% |
Balance Sheet
| Total Cash (mrq) | 20B USD |
| Total Cash Per Share (mrq) | 11.51 USD |
| Total Debt (mrq) | 2.32B USD |
| Total Debt/Equity (mrq) | 11.2 USD |
| Current Ratio (mrq) | 2.682 |
| Book Value Per Share (mrq) | 1.7801172 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 13.28B USD |
| Levered Free Cash Flow (ttm) | 4.93B USD |
Profile of Innovent Biologics
| Country | United States |
| State | N/A |
| City | Suzhou |
| Address | 168 Dongping Street |
| ZIP | 215123 |
| Phone | 86 512 6956 6088 |
| Website | https://www.innoventbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 8754 |
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Q&A For Innovent Biologics Stock
What is a current IVBXF stock price?
Innovent Biologics IVBXF stock price today per share is 12 USD.
How to purchase Innovent Biologics stock?
You can buy IVBXF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Innovent Biologics?
The stock symbol or ticker of Innovent Biologics is IVBXF.
Which industry does the Innovent Biologics company belong to?
The Innovent Biologics industry is Biotechnology.
How many shares does Innovent Biologics have in circulation?
The max supply of Innovent Biologics shares is 1.74B.
What is Innovent Biologics Price to Earnings Ratio (PE Ratio)?
Innovent Biologics PE Ratio is 120.00000000 now.
What was Innovent Biologics earnings per share over the trailing 12 months (TTM)?
Innovent Biologics EPS is 0.1 USD over the trailing 12 months.
Which sector does the Innovent Biologics company belong to?
The Innovent Biologics sector is Healthcare.
